Begum Rujina, Mir Summon, Lee Brian
Emergency Medicine, Midland Metropolitan University Hospital, Birmingham, GBR.
Geriatrics, Midland Metropolitan University Hospital, Birmingham, GBR.
Cureus. 2024 Nov 11;16(11):e73476. doi: 10.7759/cureus.73476. eCollection 2024 Nov.
Denosumab is a human monoclonal immunoglobulin G2 (IgG2) antibody that is used in the management of osteoporosis and various bone-related disorders to help strengthen bones and prevent fractures. Declining renal function and the drug denosumab are both associated with an increased risk of hypocalcaemia. The combination of both factors in a patient, along with the long half-life of the drug, can cause further exacerbation of this risk. A thorough understanding of pharmacokinetics is therefore essential when encountering drug adverse effects. We present a case of recurrent severe hypocalcaemia secondary to denosumab administration in a patient with chronic kidney disease. This case report highlights the importance of close monitoring of calcium levels in patients with established risk factors for hypocalcaemia, as well as in those who have achieved resolution of denosumab-induced hypocalcaemia.
地诺单抗是一种人源单克隆免疫球蛋白G2（IgG2）抗体，用于治疗骨质疏松症和各种与骨骼相关的疾病，以帮助增强骨骼并预防骨折。肾功能下降和药物地诺单抗均与低钙血症风险增加有关。患者同时存在这两个因素，再加上药物的长半衰期，会导致这种风险进一步加剧。因此，在遇到药物不良反应时，全面了解药代动力学至关重要。我们报告一例慢性肾脏病患者因使用地诺单抗继发反复严重低钙血症的病例。本病例报告强调了密切监测有低钙血症既定危险因素患者以及地诺单抗所致低钙血症已得到缓解患者血钙水平的重要性。
